机构：[1]Lung Cancer Center & Institute, West China Hospital, Sichuan University, Chengdu, 610041, China四川大学华西医院[2]Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, 610041, China四川大学华西医院[3]Department of Pathology, Immunology, Key Laboratory of Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine, Shihezi, 832000, China
Wu Jieping Medical Foundation, China (312150082), Science and Technology Plan Project, Sichuan Province, China (2019YFS0335) and Regional Cooperation Plan, Guizhou Province, China([2014]7004).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类|2 区医学
小类|2 区肿瘤学2 区呼吸系统
最新[2025]版：
大类|2 区医学
小类|3 区肿瘤学3 区呼吸系统
第一作者：
第一作者机构：[1]Lung Cancer Center & Institute, West China Hospital, Sichuan University, Chengdu, 610041, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Zhai Xiaoqian,Wu Qiang,Zeng Zhen,et al.OFCC1-ALK (Ointergenic: A20): A novel OFCC1 intergenic region-ALK fusion identified from a lung adenocarcinoma patient.[J].Lung cancer (Amsterdam, Netherlands).2021,153:171-173.doi:10.1016/j.lungcan.2020.12.034.
APA：
Zhai Xiaoqian,Wu Qiang,Zeng Zhen,Suo Jing,Lin Feng&Zhou Qinghua.(2021).OFCC1-ALK (Ointergenic: A20): A novel OFCC1 intergenic region-ALK fusion identified from a lung adenocarcinoma patient..Lung cancer (Amsterdam, Netherlands),153,
MLA：
Zhai Xiaoqian,et al."OFCC1-ALK (Ointergenic: A20): A novel OFCC1 intergenic region-ALK fusion identified from a lung adenocarcinoma patient.".Lung cancer (Amsterdam, Netherlands) 153.(2021):171-173
